3 Trials Confirm Ticagrelor Reduces Bleeding, Does Not Increase Thromboembolic Events vs. DAPT
2 TWILIGHT substudies, TICO trial compare ticagrelor only to ticagrelor plus aspirin 3 months after PCI
Three key late-breaking clinical trials confirmed that ticagrelor without aspirin following percutaneous coronary intervention (PCI) lowers bleeding risk and does not raise thromboembolic risk in comparison with ticagrelor-plus-aspirin therapy across several different types of patients, according to results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.